Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients

Lenalidomide Combined With R-CHOP in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients

Patrocinadores

Patrocinador principal: Fudan University

Fuente Fudan University
Resumen breve

In this phase II study, the investigators are aiming to explore lenalidomide combined with R-CHOP (R2-CHOP) in newly diagnosed double-expressor Diffuse Large B-Cell Lymphoma patients (DLBCL)

Descripción detallada

Double expressor lymphoma is a subtype of diffuse large B-cell lymphoma defined as having increased expression of MYC and BCL-2 by immunohistochemistry. Patients with double-expressor lymphomas have a poor prognosis when treated with standard chemoimmunotherapy and have increased risk of progression and recurrence. The investigators conducted this study to evaluate the efficacy of lenalidomide combined with R-CHOP (R2-CHOP) in newly diagnosed double-expressor, untreated Diffuse Large B-Cell Lymphoma patients (DLBCL). Lenalidomide is the second-generation immunomodulatory drug, and its anti-tumor mechanism may involve immunomodulatory, antiinflammatory, and antiangiogenic effects and suppression of tumor necrosis factor-alpha (TNF-α) from peripheral blood mononuclear cells. In this phase II study, the investigators are aiming to explore lenalidomide combined with R-CHOP (R2-CHOP) in newly diagnosed double-expressor Diffuse Large B-Cell Lymphoma patients (DLBCL), in order to find a potential promising way to treat this kind of disease.

Estado general Recruiting
Fecha de inicio October 22, 2019
Fecha de Terminación October 2021
Fecha de finalización primaria October 2021
Fase Phase 2
Tipo de estudio Interventional
Resultado primario
Medida Periodo de tiempo
2-year progression free survival From date of patients sign informed consent until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
Resultado secundario
Medida Periodo de tiempo
objective response rate at the end of Cycle 6 (each cycle is 21 days)
overall survival From date of patients sign informed consent until the date of death or the date of last follow-up time, whichever came first, assessed up to 2 years
Hematology and non hematology toxicity Throughout the treatment period,up to 6 months
Inscripción 62
Condición
Intervención

Tipo de intervención: Drug

Nombre de intervención: Lenalidomide combined with R-CHOP

Descripción: rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Lenalidomide 25mg PO QD D2-11

Etiqueta de grupo de brazo: R2-CHOP

Otro nombre: R2-CHOP

Elegibilidad

Criterios:

Inclusion Criteria:

1. Age range 18-75 years old

2. Eastern Cooperative Oncology Group performance status 0 to 2;

3. Newly diagnosed, untreated, histological confirmed diffuse large B cell lymphoma, and Myc≥40% as well as Bcl-2≥50% through immunohistochemistry;

4. Measurable disease was defined as at least one lesion ≥1.5 cm in length-diameter and ≥1.0cm in short-diameter by CT or MRI.

5. White blood cell ≥ 3.5×109/L, absolute neutrophil count ≥ 1.5×109/L,platelet ≥ 80×109/L,hemoglobin ≥ 90 g/L. If abnormal factors of peripheral blood caused by bone marrow or spleen involvement of lymphoma, whether to enroll depends on the judgment of researchers

6. Total bilirubin < 1.5×upper limit of normal(ULN), ALT and AST < 1.5× ULN

7. serum creatine <1.5×ULN, and creatinine clearance rate (CCR) ≥ 40 ml/min

8. Ultrasonic cardiogram or nuclide cardiac function showed left ventricle ejection fraction ≥ 50%

9. Women of childbearing potential and men who are sexually active are consent to practicing a highly effective method of birth control. Women of childbearing potential must have a negative serum β-hCG within 2 weeks of enrollment

10. Patients have written informed consent to participate in the study.

Exclusion Criteria:

1. Prior sever allergy to humanized or mouse derived monoclonal antibody. Unable to receive either lenalidomide or R-CHOP background chemotherapy.

2. History of myocardial diseases, such as unstable angina pectoris, acute myocardial infarction within 6 months of enrollment, congenital heart failure NYHA III/IV

3. Particular kind of DLBCL,such as primary mediastinal/thymic B-cell lymphoma, EBV positive DLBCL, primary cutaneous large B lymphoma, leg type.

4. Presence of CNS involvement

5. Having surgeries ≥ grade 2 within 3 weeks of enrollment.

6. History or now in the treatment process of other malignancies except cured basal cell carcinoma of skin (melanoma not included), and carcinoma in-situ of uterine cervix.

7. More than grade 3 neurotoxicity within 2 two weeks of enrollment

8. Receiving any treatment for lymphoma except short use of corticosteroid (no more than 10 days)

9. History of deep vein thrombosis or pulmonary embolism within 12 months of enrollment

10. Unable or reject to receive antithrombotic treatment

11. Presence of active HBV infection (HBsAg positive and HBV-DNA≥ 104), HCV infection, acquired and congenital immunodeficiency diseases include but not limited to HIV

12. Pregnant or lactating women

13. Previously received organ transplant

14. Serious uncontrolled infection

15. Having contraindications to the use of large doses of hormone, such as uncontrolled hyperglycemia, gastric ulcer, mental disorder.

16. Severe neurol of mental illness, including dementia and epilepsy.

17. Drug abuse, medical, psychological or social conditions which may interfering with subjects' participation in the study or evaluation of the results

18. Patients considered unsuitable to participate in the study by the researchers

Género: All

Edad mínima: 18 Years

Edad máxima: 75 Years

Voluntarios Saludables: No

Oficial general
Apellido Papel Afiliación
Junning Cao Principal Investigator Fudan University
Contacto general

Apellido: Junning Cao

Teléfono: +86-21-64175590

Email: [email protected]

Ubicación
Instalaciones: Estado: Contacto: 270 Dongan Road, Fudan University Shanghai Cancer Center Junning Cao [email protected]
Ubicacion Paises

China

Fecha de verificación

November 2019

Fiesta responsable

Tipo: Principal Investigator

Afiliación del investigador: Fudan University

Nombre completo del investigador: Junning Cao, MD

Título del investigador: Principal Investigator

Tiene acceso ampliado No
Condición Examinar
Número de brazos 1
Grupo de brazo

Etiqueta: R2-CHOP

Tipo: Experimental

Descripción: Lenalidomide combined with rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone

Datos del paciente No
Información de diseño del estudio

Asignación: N/A

Modelo de intervención: Single Group Assignment

Propósito primario: Treatment

Enmascaramiento: None (Open Label)

Fuente: ClinicalTrials.gov